New data on targeted breast cancer drugs from everyday practice

NCT ID NCT06504719

Completed Knowledge-focused Sponsor: Hellenic Cooperative Oncology Group Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed study looked at 312 patients with advanced breast cancer who received either trastuzumab deruxtecan or sacituzumab govitecan. Researchers collected real-world information on side effects and how long the cancer was kept under control. The goal was to see how these drugs perform outside of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab deruxtecan and sacituzumab govitecan (antibody-drug conjugates)
What this could lead to: If the results are positive, this could help doctors better understand how these drugs work in everyday practice and guide treatment decisions for advanced breast cancer.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by patient selection and other factors. It does not prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer breast cancer breast carcinoma breast neoplasm metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER METASTATIC CANCER

Contacts and locations

Locations

Hellenic Cooperative Oncology Group

Athens, 11524, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.